✦ LIBER ✦

A phase I study of carboplatin in children with acute leukemia in bone marrow relapse: A report from the childrens cancer group

✍ Scribed by Lawrence J. Ettinger; Mark D. Krailo; Paul S. Gaynon; G. Denman Hammond

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 576 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930801)72:3<917::aid-cncr2820720342>3.0.co;2-q

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of carboplatin as a tre

A Phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow : A report of the Children's Cancer Group

✍ Lawrence J. Ettinger; Percy Ivy; Paul S. Gaynon; Alice G. Ettinger; Wen Liu-Mare 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 3 views

## BACKGROUND. Carboplatin is an analogue of cisplatin with less nonhematologic toxicity

Improvement in outcome for children with

Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the childrens cancer study group

✍ Jonathan D. Buckley; Ronald L. Chard; Robert L. Baehner; Mark E. Nesbit; Beatric 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 888 KB

The Childrens Cancer Study Group conducted four therapeutic studies on a total of 1006 children with acute nonlymphocytic leukemia from 1972 to 1983. This report describes the therapeutic strategies of these studies and examines trends in induction rates and long-term outcome over this period. The r

A phase II study of carboplatin in child

A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the childrens cancer group

✍ Lawrence J. Ettinger; Paul S. Gaynon; Mark D. Krailo; Ning Ru; Edward S. Baum; S 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 3 views

Background. Carboplatin is an analogue of cisplatin with less nonhematologic toxicity than

Treatment of overt isolated testicular r

Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the childrens cancer group

✍ Jerry Z. Finklestein; Denis R. Miller; James Feusner; Daniel O. Stram; Edward Ba 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 512 KB

Successful reinduction therapy with amsa

Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the childrens cancer study group

✍ Linda P. Miller; Allan F. Pyesmany; Lawrence J. Wolff; Paul C. J. Rogers; Stuart 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 644 KB

Amsacrine (AMSA) and cyclocytidine were studied as retrieval therapy in 122 pediatric patients with acute nonlymphoblastic leukemia (ANLL). Patients either failed to achieve sustained initial remissions or were in relapse. Induction therapy consisted of intravenous (IV) AMSA (75 mg/mz) from days 1 t

Phase I/II study of bisantrene in childh

Phase I/II study of bisantrene in childhood cancer: A report from the childrens cancer study group

✍ Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect